Celon Pharma (FRA:8RP) FCF Margin % : -37.82% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Celon Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Celon Pharma's Free Cash Flow for the three months ended in Sep. 2024 was €-4.70 Mil. Celon Pharma's Revenue for the three months ended in Sep. 2024 was €12.43 Mil. Therefore, Celon Pharma's FCF Margin % for the quarter that ended in Sep. 2024 was -37.82%.

As of today, Celon Pharma's current FCF Yield % is -2.38%.

The historical rank and industry rank for Celon Pharma's FCF Margin % or its related term are showing as below:

FRA:8RP' s FCF Margin % Range Over the Past 10 Years
Min: -68.46 Med: -20.47 Max: 6.98
Current: -18.25

During the past 9 years, the highest FCF Margin % of Celon Pharma was 6.98%. The lowest was -68.46%. And the median was -20.47%.

FRA:8RP's FCF Margin % is ranked worse than
78.87% of 970 companies
in the Drug Manufacturers industry
Industry Median: 0.89 vs FRA:8RP: -18.25

Celon Pharma FCF Margin % Historical Data

The historical data trend for Celon Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celon Pharma FCF Margin % Chart

Celon Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-68.46

-20.47

1.53

-23.84

-25.02

Celon Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															4.98	2.02	-17.76	-15.44	-37.82

Competitive Comparison of Celon Pharma's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celon Pharma's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Celon Pharma's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Celon Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Celon Pharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-10.071	/	40.256
	=	-25.02 %

Celon Pharma's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-4.7	/	12.427
	=	-37.82 %

Celon Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Celon Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Celon Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celon Pharma SA (FRA:8RP) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CLN:Poland

Address

Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092

Website

http://www.celonpharma.com

Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.

Celon Pharma Headlines

No Headlines